Chemical inhibitors of C20orf77 function through various biochemical mechanisms to inhibit the protein's activity. Staurosporine, a well-known protein kinase inhibitor, disrupts the phosphorylation events that are critical for the activity of many proteins, including C20orf77. By inhibiting these kinases, Staurosporine can prevent the phosphorylation that C20orf77 might require for its function. Similarly, Wortmannin and LY294002, both phosphoinositide 3-kinases (PI3K) inhibitors, disrupt signaling pathways that C20orf77 relies upon. By inhibiting PI3K, these chemicals can prevent the activation of downstream targets that may be essential for the function of C20orf77. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can also disrupt downstream signaling pathways associated with C20orf77, potentially inhibiting its function. This is similar to the action of U0126 and PD98059, which selectively inhibit MEK1/2 and MEK respectively, thereby preventing the activation of the ERK pathway, a pathway that C20orf77 may depend on for its activity.
Furthermore, SB203580 targets p38 MAP Kinase, which is involved in response to stress and cytokines. Inhibition of p38 MAPK by SB203580 can interrupt signaling cascades that C20orf77 is part of, leading to its inhibition. SP600125, a JNK inhibitor, can halt signaling processes that are essential for C20orf77's activity. Triciribine aims at AKT inhibition, which prevents the phosphorylation and activation of proteins that are in the same pathway as C20orf77, thus leading to its functional inhibition. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can suppress the activity of kinases that regulate the activity of proteins such as C20orf77. Leflunomide inhibits dihydroorotate dehydrogenase, which can reduce the synthesis of proteins that are part of C20orf77's pathway, resulting in functional inhibition. Lastly, Bortezomib, as a proteasome inhibitor, causes the accumulation of misfolded proteins, disrupting cellular homeostasis and potentially inhibiting the function of C20orf77 through stress-induced pathways. Each chemical operates by disrupting specific pathways or cellular processes that are crucial for the proper functioning of C20orf77, thereby achieving inhibition.
関連項目
Items 1 to 10 of 12 total
画面:
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
スタウロスポリンはプロテインキナーゼを阻害し、C20orf77の活性に必要なリン酸化イベントの阻害につながる可能性がある。 | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmanninはホスホイノシチド3-キナーゼの阻害剤であり、C20orf77がその機能に依存しているシグナル伝達経路を破壊する可能性がある。 | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
もう一つのPI3K阻害剤であるLY294002も、C20orf77の機能に必要な経路を破壊する可能性がある。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
ラパマイシンはmTORを阻害し、これはC20orf77の機能を制御するシグナル伝達経路に対する下流の効果に必要かもしれない。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126はMEK1/2を選択的に阻害し、C20orf77の活性に重要なERK経路を遮断する可能性がある。 | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059はMEKを阻害し、C20orf77の機能に必要なステップであるERK経路の活性化を阻害する可能性がある。 | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580はp38 MAPキナーゼを特異的に標的とし、C20orf77が関与するシグナル伝達カスケードを阻害する可能性がある。 | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125はJNKを阻害し、C20orf77の活性に不可欠なシグナル伝達プロセスを停止させる可能性がある。 | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
トリシリビンはAKTを阻害するため、C20orf77と同じ経路のタンパク質のリン酸化と活性化が阻害される可能性がある。 | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
ダサチニブは幅広いチロシンキナーゼ阻害剤であり、C20orf77の制御に関与するキナーゼの活性を抑制する可能性がある。 |